AZD0780

Phase 3Small molecule

AstraZeneca

AZD0780 is one of 58 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

HypercholesterolaemiaActive, not recruiting

DyslipidaemiaActive, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

HypercholesterolaemiaPhase 3

Active, not recruiting

DyslipidaemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Cardene

Sun Pharmaceutical Industries, Inc.

Primacor

Geodon

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Midamor

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Dyslipidaemia

NCT07218900

Q1 2027

Phase 3Active, not recruiting

Hypercholesterolaemia

NCT07000136

Phase 3Active, not recruiting

Cardiovascular Disease

NCT07000123

PreclinicalActive, not recruiting

Dyslipidaemia

NCT06834932

Q4 2029

Phase 3Recruiting

Cardiovascular Disease

NCT07000357

Clinical

Trials by Indication[1]

Dyslipidemia2 trials

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06173570·428 enrolled

A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05384262·183 enrolled

Dyslipidaemia2 trials

A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 in Combination With Rosuvastatin on Low Density Lipoprotein Cholesterol in Participants With Dyslipidaemia (LAZURE)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07218900·76 enrolled

A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants With Dyslipidaemia (AZURE-CHINA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06834932·432 enrolled

Cardiovascular Disease2 trials

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000357·15,100 enrolled

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000123·3,103 enrolled

Hepatic Impairment1 trial

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06576765·16 enrolled

Statin1 trial

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05787002·16 enrolled

8 more indications

Efficacy1 trial

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06742853·81 enrolled

DME1 trial

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05817461·8 enrolled

Blood Pressure1 trial

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06692764·202 enrolled

Metformin1 trial

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT07216131·14 enrolled

Renal Impairment1 trial

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06592482·30 enrolled

Drug Interactions1 trial

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06671405·59 enrolled

Hypercholesterolaemia1 trial

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000136·473 enrolled

Unspecified1 trial

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Repeated Dose Administration to Healthy Adults With Elevated LDL-C Levels

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT07423598·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for AZD0780. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0780 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0780. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

AZD0780

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q4 2029

Trials by Indication[1]

Dyslipidemia2 trials

Dyslipidaemia2 trials

Cardiovascular Disease2 trials

Hepatic Impairment1 trial

Statin1 trial

Efficacy1 trial

DME1 trial

Blood Pressure1 trial

Metformin1 trial

Renal Impairment1 trial

Drug Interactions1 trial

Hypercholesterolaemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News